ProCE Banner Activity


Transforming the Care of Patients with Non-Small-Cell Lung Cancer: Optimizing Immune Checkpoint Inhibitor Therapy

PCE On Demand Live Presentation

Immune checkpoint inhibitors (ICIs) are recommended for various patients with non-small-cell lung cancer (NSCLC). Healthcare professionals (HCPs) must be familiar with current expert recommendations for use of ICIs as results of biomarker testing, and PD-L1 levels can influence choice of therapy. Once ICIs are used, HCPs need to be aware of the potential for immune-related adverse events (irAEs). In this video lecture, an expert discusses strategies for optimizing ICIs in advanced NSCLC including individualizing therapy decisions and managing adverse events

Download the PDF Resource "Immune Checkpoint Inhibitor Therapy in NSCLC: Current Approved Indications and Toxicity Management."

Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Released: July 14, 2022

Expiration: July 13, 2023

No longer available for credit.



Sandip P. Patel

Sandip P. Patel, MD

Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California San Diego
San Diego, California

Beth Sandy

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania


This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, Merck Sharp & Dohme Corp., and Regeneron Pharmaceuticals, Inc. and Sanofi.

Provided by

ProCE Banner


Bristol Myers Squibb

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc.


Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify currently approved ICIs and the role of biomarker testing in their use in advanced NSCLC

  • Describe recommended, evidence-based strategies to individualize treatment with ICIs for patients with advanced NSCLC

  • Implement effective strategies for identification and management of irAEs in patients treated with ICIs


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Sandip P. Patel, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Eli Lilly, Genentech, Illumina, Merck, Pfizer, and Rakuten Medical; researcher: Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Iovance Biotherapeutics, Merck, Pfizer.

Beth Sandy, MSN, CRNP: consultant: Amgen, AstraZeneca, Janssen, Jazz, Merck, Takeda.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Beth Sandy, MSN, CRNP as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: July 14, 2022
Expiration date: July 13, 2023


On-demand webcast


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit

NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until July 13, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.